FSGS AWARENESS DAY

Illinois General Assembly - Full Text of SR0757

Select Language

×

The Illinois General Assembly offers the Google Translate™ service for visitor convenience. In no way should it be considered accurate as to the translation of any content herein.

Visitors of the Illinois General Assembly website are encouraged to use other translation services available on the internet.

The English language version is always the official and authoritative version of this website.

NOTE: To return to the original English language version, select the "Show Original" button on the Google Translate™ menu bar at the top of the window.

Choose Language

English

Afrikaans

Albanian

Arabic

Armenian

Azerbaijani

Basque

Bengali

Bosnian

Catalan

Croatian

Czech

Danish

Dutch

Esperanto

Estonian

Filipino

Finnish

French

Galician

Georgian

German

Greek

Gujarati

Haitian Creole

Hausa

Hawaiian

Hebrew

Hindi

Hungarian

Icelandic

Indonesian

Interlingua

Interlingue

Inuktitut

Irish

Italian

Japanese

Javanese

Kannada

Khmer

Korean

Latin

Latvian

Lithuanian

Luxembourgish

Macedonian

Malagasy

Malayalam

Maltese

Maori

Marathi

Myanmar

Nepali

Norwegian

Odia

Pashto

Punjabi

Romanian

Russian

Samoan

Sango

Sanskrit

Sardinian

Sindhi

Sinhala

Slovak

Slovenian

Somali

Southern Sotho

Spanish

Sundanese

Swahili

Swedish

Tamil

Telugu

Thai

Tigrinya

Tonga

Turkish

Ukrainian

Urdu

Vietnamese

Welsh

Xhosa

Yiddish

Yoruba

Zulu

Powered by
Translate

Close

Illinois General Assembly

Top Navigation Bar

Translate

Learn

Select General Assembly

Search the 104th General Assembly

Enter search terms for legislation, members, committees, or schedules.

ILGA.GOV

LEGISLATION & LAWS

Bills & Resolutions

Public Acts

Illinois Compiled Statutes

Illinois Constitution

Search Legislation

Glossary

Guide

Reports & Inquiry

Legislative Reports

Special Reports

FTP Site

Legislator Lookup

Capitol Complex Phone Numbers

Rules & Regulations

Illinois Register

Administrative Rules

Senate

Members

Schedules

Committees

Request for Remote Testimony

Journals

Transcripts

Rules

Audio/Video

FOIA Information

Senate Employment Opportunities

Media Guidelines

House

Members

Schedules

Committees

Submit testimony for House Committees

Journals

Transcripts

Rules

Audio/Video

FOIA Information

House Employment Opportunities

Log In

Mobile Top Bar

Search the 104th General Assembly

Enter keywords to search the Illinois General Assembly website.

Full Text of SR0757

Home

Legislation

Full Text

SR0757 - 104th General Assembly

Bill Status

Full Text

Votes

Witness Slips

Select Menu

Bill Status

Full Text

Votes

Witness Slips

Printer Friendly Version

Introduced

Printer Friendly Version

Introduced

Open PDF

SR0757
LRB104 21607 RMO 37068 r
1
SENATE RESOLUTION

2

WHEREAS, Approximately 1 in 7 American adults have chronic
3
kidney disease, and the third leading cause of chronic kidney
4
disease is glomerulonephritis, often caused by rare kidney
5
diseases such as focal segmental glomerulosclerosis (FSGS);
6
and

7

WHEREAS, FSGS is a condition referring to scarring in the
8
kidneys, often leading to a difficult journey that can, in
9
many cases, result in kidney failure, requiring dialysis,
10
transplants, and cycles of remissions and relapse; and

11

WHEREAS, Of patients with FSGS, 50% of them require
12
dialysis or a kidney transplant within 5 to 10 years of
13
diagnosis; and

14

WHEREAS, FSGS is a severe disease because it often
15
progresses rapidly to kidney failure, and even for patients
16
who receive a kidney transplant, it can recur in their
17
transplanted kidney up to 50% of the time; and

18

WHEREAS, While FSGS can be diagnosed at any age, it is most
19
commonly diagnosed in adults rather than in children and most
20
prevalent in adults over 45 years of age; and

SR0757
- 2 -
LRB104 21607 RMO 37068 r
1

WHEREAS, FSGS is a burden on our healthcare system, with a
2
2019 study estimating that the disease costs Medicaid,
3
Medicare, and private health insurance approximately $2
4
billion annually in direct medical costs, not including
5
indirect and quality of life costs; and

6

WHEREAS, According to data from the National Registry of
7
Rare Kidney Diseases (RaDaR), rare kidney diseases such as
8
FSGS comprise only 5% to 10% of chronic kidney disease
9
patients but account for approximately 30% of kidney failure;
10
and

11

WHEREAS, Many patients face delays in being diagnosed with
12
FSGS, due both to the difficulty of the rare disease
13
diagnostic odyssey, averaging 5 to 7 years, and challenges in
14
accessing nephrology care that specialize in rare kidney
15
diseases due to the current shortage in the United States; and

16

WHEREAS, FSGS disproportionately impacts minority
17
populations, including African Americans, often occurring at a
18
rate 4 to 5 times higher than white Americans; and

19

WHEREAS, Due to certain variants of the APOL1 gene that
20
significantly increase the risk of developing FSGS and other
21
kidney diseases and the fact that these high-risk variants are
22
found almost exclusively in individuals of African ancestry,

SR0757
- 3 -
LRB104 21607 RMO 37068 r
1
the condition contributes to the disproportionate burden of
2
kidney disease in Black communities; and

3

WHEREAS, FSGS is a significant burden not only to the
4
health and lives of patients and their families but also
5
because the condition incurs great challenges for the
6
healthcare system and healthcare financing in Illinois; and

7

WHEREAS, There is new hope for patients with FSGS, as
8
clinical trials are underway for products that may delay
9
progression of the condition and the onset of kidney disease,
10
including the first FDA-approved therapy in April 2026, and
11
significant progress is being made by scientists, regulators,
12
patient groups, and industry through the PARASOL, or
13
Proteinuria and GFR as Clinical Trial Endpoints in FSGS,
14
Project to validate proteinuria as an indicator of improvement
15
in patients; and

16

WHEREAS, Patients, families, advocacy organizations such
17
as NephCure, healthcare providers, the healthcare industry,
18
and researchers are working tirelessly to raise awareness,
19
promote early detection, and develop new innovative therapies
20
for FSGS patients and those living with other rare kidney
21
diseases in Illinois; and

22

WHEREAS, FSGS Awareness Day is designated to raise

SR0757
- 4 -
LRB104 21607 RMO 37068 r
1
awareness of FSGS, to provide support and inspiration to
2
patients and families struggling with the disease, and to
3
promote the efforts needed for better diagnosis and access to
4
future treatments that can transform the course of the
5
condition; therefore, be it

6

RESOLVED, BY THE SENATE OF THE ONE HUNDRED FOURTH GENERAL
7
ASSEMBLY OF THE STATE OF ILLINOIS, that we declare June 9, 2026
8
as FSGS Awareness Day in the State of Illinois to bring
9
attention to focal segmental glomerulosclerosis (FSGS)
10
disease.

Footer

Disclaimer

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.

Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn

This site is maintained for the Illinois General Assembly by the
Legislative Information System, 705 Stratton Building, Springfield, Illinois 62706.
Contact ILGA Webmaster

ILGA.gov uses cookies to ensure you get the best experience on our website. By continuing to browse ILGA.gov you consent to our use of cookies.
Read About Cookies

ILGA.GOV

2026 ILGA.gov | All Rights Reserved |
ADA

|
Disclaimers
|
Learn